CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance. Coverage is effective April 1, 2023. AlloMap Heart and AlloSure Heart are also covered by Medicare individually.
https://finance.yahoo.com/news/caredx-heartcare-multimodality-receives-medicare-110000688.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.